Poly Medicure Ltd Q1 FY26 – 27% Margins, 334 Patents, and 90% of PendraCare (But Still Trading at 56x P/E Like It Cures Hangovers)
1. At a Glance
Poly Medicure (Polymed) isn’t just another midcap—it’s the rare Indian company exporting syringes and catheters instead of IT engineers. With a ₹20,000+ Cr market cap, 27% operating margins, and sales in 100+ countries, the company has quietly become the “Medtronic lite” of India. Problem? The market prices it like it’s inventing AI-driven robotic surgeons, not plastic tubes—56x P/E, anyone?
2. Introduction
In a country where investors worship FMCG and IT, Polymed is the silent overachiever in the medical device corner. It’s the nerd in class who doesn’t make reels but still tops every exam. They manufacture infusion therapy kits, blood bags, catheters, dialysis disposables—basically, all the stuff you hope never gets near you, but you want to be world-class if it does.
And they don’t just sell in India; they export more than half their devices to Europe and the U.S.—markets that don’t forgive quality slips. Imagine an Indian company convincing German doctors to trust its catheters. That’s harder than convincing your dadi to trust Swiggy biryani.
The stock’s journey has been like a treadmill: solid 20%+ CAGR in sales and profits for a decade, but recently, the market caught its breath (-15% return in the last year). Why? Maybe because at 56x P/E, investors want it to not only supply hospitals but also cure the healthcare system itself.
So, is Polymed the undisputed “syringe king,” or is it just being priced like the next vaccine manufacturer waiting for another pandemic wave? Let’s insert the needle and check.
3. Business Model – WTF Do They Even Do?
Polymed’s model is simple: manufacture 1.7 billion disposable medical devices a year, across 200+ products, and sell them in 100+ countries. Think of it as the Amul of medical disposables—consistent, boring, necessary.
Geography: India (30%), Europe (32%), Rest of World (38%). Basically, if you fall sick in Africa or Europe, chances are a Polymed device will poke you.
Their moat? Backward integration (12 plants, 3 more coming), global patents (334 granted), and MDR certification in EU for 54 products. That’s like getting CBSE approval on steroids.
Question: Would you rather back an IT company fighting 10,000 start-ups, or a med-device company fighting just B Braun and Fresenius?
4. Financials Overview
Quarterly Snapshot (₹ Cr):
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
403
385
441
4.8%
-8.6%
EBITDA
106
104
119
1.9%
-10.9%
PAT
93
74
92
25.7%
1.1%
EPS (₹)
9.2
7.7
9.1
18.8%
1.0%
Commentary: Revenues slowed a bit, but PAT margin flexed like a gym bro—up 26%. EPS annualised at ~₹36, so forward P/E still at nosebleed 55x. Investors, breathe in through catheter, breathe out slowly.
5. Valuation Discussion – Fair Value Range
P/E Method: TTM EPS: ₹35.3 Sector median P/E: ~40–50 → Fair Value Range: ₹1,400 –
